ArticleBMJ public health2026
Proactive case-finding and risk-stratification in people at risk of chronic liver disease in Greater Manchester: a cost-effectiveness analysis.
Article in BMJ public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: We urgently need innovative strategies to combat a growing epidemic of chronic liver disease (CLD). Integrated Diagnostics for Early Detection of Liver Disease (ID-LIVER) was a collaborative project aiming to improve detection of reversible-stage CLD in a region with high prevalence of critical risk factors. This study assesses the cost-effectiveness of different ways to identify people with significant CLD (defined as METAVIR stage F2 or higher, using liver stiffness of ≥8 kPa on transient elastography as a proxy measure). Strategies of interest include proactive case-finding in the community (supplementing a reactive pathway where hepatology referrals are passively received from primary care) and/or risk-stratification (using Fibrosis-4 (FIB-4) or ID-LIVER-Machine Learning (ML)-a novel machine-learning risk-stratification tool). Methods: We developed a state-transition decision-analytic model estimating lifetime healthcare costs (2023/2024 GBP) and quality-adjusted life-years (QALYs) associated with six alternative strategies for case-finding and risk-stratification. We simulated cohorts of people with alcohol-related liver disease and metabolic dysfunction-associated steatotic liver disease. We populated the model with data collected in ID-LIVER, supplemented by parameters from the literature and routine data sources. We estimated incremental cost-effectiveness and performed deterministic and probabilistic sensitivity analyses. Results: Any case-identification strategy costing ≤£3300 per person with significant CLD identified would meet English cost-effectiveness thresholds (£20 000/QALY). In our decision set, the cheapest strategy is to use FIB-4 in the reactive-only population; however, this misses 43.6% of people with significant CLD. ID-LIVER-ML (using a cut-off of 0.4) generates more population health at a reasonable cost (£10 498/QALY gained). Introducing proactive case-finding generates further health benefits, costing £12 952/QALY gained. Using ID-LIVER-ML in the proactive-and-reactive population has the highest probability of maximising cost-effectiveness, when valuing QALYs at £20 000. Conclusions: Smart methods of case-finding and risk-stratification identify people with significant CLD in the community and are likely to represent good value for money in England.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.